- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Agfa to acquire European maker of contrast media
Agfa HealthCare has signed an agreement with Curagita Holding AG to acquire all the shares of its subsidiary Insight Agents GmbH, a German-based developer and producer of generic contrast media.
Agfa HealthCare has signed an agreement with Curagita Holding AG to acquire all the shares of its subsidiary Insight Agents GmbH, a German-based developer and producer of generic contrast media. Agfa expects to pay about 10 million Euros for the contrast media firm in a deal that the Belgian company is framing as an important strategic step towards future growth opportunities. Insight Agents makes generic contrast media, including the MR contrast agent Magnegita (gadopentetate dimeglumine), a generic form of Magnevist, and Iopamigita (Iopamidol), a generic form of Isovue. Insight’s contrast media are logical additions to Agfa’s portfolio of film, chemicals, and printers, according to Christian Reinaudo, president of Agfa HealthCare. They will be distributed through the company’s extensive logistics and distribution network, he said.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.
